Clinical trials: Diabetes Type II
Diabetes, Gestational, Diabetes, Type 2
Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy
The aim of this study is to compare glycemic control in pregnant women treated with insulin Detemir and pregnant women treated with NPH insulin.
- Trial name
- NCT01837680
- Testing
- Insulin
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Type 2 Diabetes
An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin
This is a single center, prospective, randomized, placebo -controlled, parallel design and double blind study to evaluate oxidative stress, inflammation and hypertension markers and mediators before and after treatment with…
- Trial name
- NCT02433678
- Testing
- dapagliflozin
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University at Buffalo
Type 2 Diabetes
Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea
This 24-weeks study will to compare the glycemic efficacy and safety of sitagliptin with pioglitazone in patients with type 2 diabetes who had inadequate glycemic control despite dual therapy with metformin and a sulfonylurea.
- Trial name
- JAS (NCT01195090)
- Testing
- Sitagliptin, pioglitazone
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Sung-Chen Liu
Diabetes Mellitus Type 2
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)
The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin therapy in adults with type 2 diabetes.
- Trial name
- IOOY (NCT00494013)
- Testing
- Insulin Lispro Protamine Suspension, Detemir
- Where
- 56 sites in United States, Argentina and 7 more
- Volunteers
- 442 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes
The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin.
- Trial name
- AWARD-6 (NCT01624259)
- Testing
- LY2189265, Liraglutide, Metformin
- Where
- 57 sites in United States, Czechia and 8 more
- Volunteers
- 599 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea
The purpose of this study is to evaluate safety by determining the incidence rates of all adverse events (AEs) including serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not…
- Trial name
- NCT04980040
- Testing
- Alogliptin Benzoate
- Where
- 22 sites in South Korea
- Volunteers
- 3,623 people
- Sponsor
- Takeda
Type 2 Diabetes
Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)
This long term, placebo-controlled trial is intended to assess the efficacy and safety of exenatide, dosed twice a day, in Japanese patients with Type 2 Diabetes who are treated with oral antidiabetic(s) but not well controlled.
- Trial name
- NCT00577824
- Testing
- exenatide
- Where
- 12 sites in Japan
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)
This study will evaluate the effect of a single dose of sitagliptin on glucose dependent insulin secretion using a meal tolerance test (MTT) during a hyperglycemic clamp (HCG) procedure.
- Trial name
- NCT00888238
- Testing
- sitagliptin
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
The main reason for this study is to compare the study drug tirzepatide to insulin glargine in participants with type 2 diabetes on metformin with or without a sulfonylurea.
- Trial name
- NCT04093752
- Testing
- Tirzepatide, Insulin Glargine
- Where
- 67 sites in Australia, China and 2 more
- Volunteers
- 917 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss.
- Trial name
- SURMOUNT-4 (NCT04660643)
- Testing
- Tirzepatide
- Where
- 70 sites in United States, Argentina and 3 more
- Volunteers
- 783 people
- Sponsor
- Eli Lilly and Company
Type II Diabetes
Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers
The primary objective of this study is to compare the rate of healing as well as percent of wounds healed in Type II diabetic patients with chronic foot ulcerations receiving sitagliptin versus placebo.
- Trial name
- NCT02015910
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Georgetown University
Sub-optimal Vitamin D Status, Pre-diabetes
Effect of Vitamin D3 Supplementation on Insulin Resistance- The DIR Study
Insulin resistance is a state where the body does not respond as it should to the insulin it produces. Individuals who are insulin resistant are at increased risk of both heart disease and type 2 diabetes; importantly, diabetes…
- Conditions
- Sub-optimal Vitamin D Status, Pre-diabetes, Insulin Resistance
- Trial name
- NCT01889810
- Testing
- Vitamin D3 supplementation
- Where
- United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Queen's University, Belfast
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.
- Trial name
- ONWARDS 1 (NCT04460885)
- Testing
- Insulin icodec, Insulin glargine
- Where
- 198 sites in United States, Croatia and 11 more
- Volunteers
- 984 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
This trial compare the use of two different doses of Empagliflozin to placebo, in T2DM patients on 16 wks linagliptin treatment and metformin background therapy.
- Trial name
- NCT01734785
- Testing
- Linagliptin, Empagliflozin + Linagliptin
- Where
- 90 sites in United States, Australia and 9 more
- Volunteers
- 607 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes
The primary purpose of this study is to evaluate the efficacy of voglibose versus acarbose combined with metformin in participants with type 2 diabetes mellitus (T2DM) by evaluating levels of glycosylated hemoglobin.
- Trial name
- NCT02049814
- Testing
- Metformin, Voglibose, Acarbose
- Where
- 18 sites in China
- Volunteers
- 494 people
- Sponsor
- Takeda
Type 2 Diabetes, Insulin Resistance
Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance
The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in…
- Conditions
- Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome
- Trial name
- NCT00443755
- Testing
- metformin, pioglitazone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Hypercholesterolemia With Type2DM
Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia
A randomized, open label, dose titration study to evaluate the efficacy and safety of Pitavastatin compared to atorvastatin in Type 2 Diabetes Mellitus with hypercholesterolemia
- Trial name
- ESPRIT (NCT00889226)
- Testing
- Pitavastatin, Atorvastatin
- Volunteers
- 161 people
- Sponsor
- JW Pharmaceutical
Type 2 Diabetes, Overweight
Mechanisms of Weight Loss With SGLT2 Inhibition
The purpose of this study is to investigate the effect of canagliflozin, a medication approved by the FDA for the treatment of type 2 diabetes, on body weight and metabolism in people with type 2 diabetes who are overweight or…
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Trial name
- NCT02360774
- Testing
- Canagliflozin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Beth Israel Deaconess Medical Center
Diabetes Mellitus, Type 2
4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
The objective of this trial is to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of once daily oral administration of BI 10773 administered for 28 days in Japanese patients with T2DM.
- Trial name
- NCT00885118
- Testing
- BI 10773
- Where
- 5 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations
The primary objective of this exploratory meta-analysis is to evaluate the frequencies, incidence rates, and hazard ratios of lower-limb amputation (LLA) events (primary outcome) and of adverse events related to amputation…
- Trial name
- NCT04937816
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 16,746 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.